Company profile: OncoResponse
1.1 - Company Overview
Company description
- Provider of immuno-oncology therapies leveraging human immune responses, with a proprietary human-antibody discovery platform sourcing antibodies from elite responder patients; OR2805 targeting M2-like tumor-associated macrophages; collaboration with MD Anderson; and a preclinical pipeline of monoclonal antibodies addressing immunosuppression in the tumor microenvironment.
Products and services
- OR2805: Lead, therapeutic-grade antibody that targets M2-like tumor-associated macrophages, aiming to enhance immunotherapy response by countering immunosuppression within tumors and augmenting anti-cancer activity
- Pipeline of monoclonal antibodies: Builds preclinical-stage monoclonal antibodies targeting immunosuppression in the tumor microenvironment, advancing candidates under development for immuno-oncology applications
- Proprietary human-antibody discovery platform: Delivers patient-sourced identification of therapeutic antibodies from elite responders, leveraging human immune system responses to create cancer immunotherapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OncoResponse
Cell Pathways
HQ: United States
Website
- Description: Provider of small molecule-based drugs for cancer treatment leveraging an apoptosis technology platform, which can be used with other chemotherapy drugs, and of kits and methods for detection and quantification, including PCR ED ELISA kits for DIG-labeled PCR products, Endothelin-1 ELISA kits for multiple species, and combined PCR-ELISA nucleic acid detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cell Pathways company profile →
OncoMed
HQ: United States
Website
- Description: Provider of biotechnology therapeutics developing monoclonal antibodies that target pathways critical to tumor-initiating (cancer stem) cells to improve cancer treatment. Pipeline includes etigilimab with nivolumab for advanced solid tumors, navicixizumab for platinum-resistant ovarian cancer (with OncXerna), setrusumab for OI, alvelestat for AATD-LD, acumapimod for AECOPD, and leflutrozole (with ReproNovo).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoMed company profile →
Valitor Bio
HQ: United States
Website
- Description: Provider of novel methods to modify therapeutic proteins for control over pharmacological properties, including VLTR-559, a long-acting treatment for wet age-related macular degeneration designed to extend a single dose to six months or more; VLTR-557, a long-acting anti-VEGF biologic with potential six-month efficacy from one intravitreal injection; and Multivalent Polymer (MVP) Technology to enhance potency, durability, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valitor Bio company profile →
HistoGeneX
HQ: Belgium
Website
- Description: Provider of biomarker technologies for translational and clinical research via CAP, CLIA, and BELAC-accredited laboratories. Offers integrated sample management and logistics, biomarker strategy support, oncology assays; flow cytometry, histopathology, genomics, immunoassays; plus CellEngine cytometry analysis software and Olink PEA protein biomarker quantification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HistoGeneX company profile →
Intradigm
HQ: United States
Website
- Description: Provider of RNA interference (RNAi) therapeutics for the treatment of serious diseases, with an initial focus on oncology. The private biotechnology company leverages drug development and delivery expertise as the foundation of its RNAi platform, including a proprietary RNAi Nanoplex delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intradigm company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OncoResponse
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OncoResponse
2.2 - Growth funds investing in similar companies to OncoResponse
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OncoResponse
4.2 - Public trading comparable groups for OncoResponse
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →